Quantum Technologies Flagship: Basel physicists participate in three research consortia

On board the quantum flagship: the three Basel physicists Prof. Nicolas Sangouard, Prof. Patrick Maletinsky and Prof. Philipp Treutlein (left to right). Photo: University of Basel, Christian Flierl

Quantum physics describes the behavior of matter at a microscopic level and forms the basis for the great technological revolutions of the last few decades. Without an understanding of quantum physics, computer and communications technology, laser and medical imaging techniques would never have been developed.

Until now, however, these technologies have not yet exploited the full potential of quantum physics, which allows for radically new phenomena: particles can be in a superposition of several states at the same time, or two distant, “entangled” particles can form such a strong unit that their properties are no longer independent of each other.

On the way to the second quantum revolution

In recent years, physicists have been able to show how they can not only observe these astonishing phenomena but also specifically control them and use them for completely new kinds of technology. These second-generation quantum technologies promise extremely powerful computers, secure communications, quantum simulators for basic research and pharmaceutics, and highly accurate sensors for use in materials science, navigation and medical technology.

Switzerland and other European countries are leading the way in university research on quantum technology. To also be at the forefront of the technology transfer to industry, the European Union has launched the Quantum Technology Flagship, a 1 billion euro funding program over a 10-year period that will give European quantum technology the decisive push towards becoming a market leader. About 140 international consortia of university research groups and industry partners applied for the first three-year funding period, of which only 20 were successful.

Success for Basel quantum physics

Researchers at the University of Basel are heavily involved in three consortia in the area of quantum optics and quantum sensing:

The MACQSIMAL project, co-founded by Professor Philipp Treutlein, is developing quantum sensors based on miniaturized atomic vapor cells. This will enable the realization of compact atomic clocks, gyroscopes, magnetic field sensors, imaging methods for microwave and terahertz fields, and gas detectors.

The technology has application potential in areas such as autonomous navigation, non-invasive medical diagnosis and drug detection. The project is firmly anchored in north-western Switzerland; it is coordinated by the research and technology organization CSEM with centers in Neuchâtel and Muttenz, who closely collaborate with the University of Basel.

The ASTERIQS consortium, which the Basel research group led by Patrick Maletinsky helped to initiate, also deals with sensors. The research alliance looks at the quantum properties of ultra-pure diamonds, which are used as precise measurement systems for quantum sensors.

They can be used to perform high-resolution measurements of magnetic and electric fields or temperatures, all of which the Basel researchers are pursuing, with a focus on applications on the nanometer scale. The innovative technologies will find applications in a broad range of semiconductor electronics, from basic research to medical diagnostics. The Basel spin-off Qnami is also an associate partner of the project, and will focus on the commercial exploitation of its results.

The Quantum Internet Alliance (QIA) project aims to develop a quantum internet that can be used to network quantum computers to powerful clusters, and for secure communication over large distances. The theoretical physicist Professor Nicolas Sangouard is involved in this project. He has already proposed numerous concepts for the realization of quantum networks, in which individual photons transfer information between network nodes.

Result of a long-term strategy

The physicists’ success is the result of a long-term strategy. “For years now, the University of Basel has built a research focus in the area of quantum technologies, which has an excellent international reputation,” explains Treutlein, who is also the Dean of Research in the Faculty of Science. “This is also reflected in the successful acquisition of prestigious externally funded research projects, such as the Quantum Technologies Flagship.” The participating researchers, who belong to the Department of Physics and the Swiss Nanoscience Institute (SNI), are highly motivated to put their research findings into practice.

Prof. Dr. Philipp Treutlein, University of Basel, Department of Physics, Tel. +41 61 207 37 66, email: philipp.treutlein@unibas.ch

Media Contact

Reto Caluori Universität Basel

More Information:

http://www.unibas.ch

All latest news from the category: Physics and Astronomy

This area deals with the fundamental laws and building blocks of nature and how they interact, the properties and the behavior of matter, and research into space and time and their structures.

innovations-report provides in-depth reports and articles on subjects such as astrophysics, laser technologies, nuclear, quantum, particle and solid-state physics, nanotechnologies, planetary research and findings (Mars, Venus) and developments related to the Hubble Telescope.

Back to home

Comments (0)

Write a comment

Newest articles

A new look at the consequences of light pollution

GAME 2024 begins its experiments in eight countries. Can artificial light at night harm marine algae and impair their important functions for coastal ecosystems? This year’s project of the training…

Silicon Carbide Innovation Alliance to drive industrial-scale semiconductor work

Known for its ability to withstand extreme environments and high voltages, silicon carbide (SiC) is a semiconducting material made up of silicon and carbon atoms arranged into crystals that is…

New SPECT/CT technique shows impressive biomarker identification

…offers increased access for prostate cancer patients. A novel SPECT/CT acquisition method can accurately detect radiopharmaceutical biodistribution in a convenient manner for prostate cancer patients, opening the door for more…

Partners & Sponsors